Interleukin Patents (Class 424/85.2)
  • Patent number: 11447551
    Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: September 20, 2022
    Assignee: SparX Bioscience Limited
    Inventors: Guidong Zhu, Jingdong Ye, Jingdong Qin, Jichun Ma
  • Patent number: 11442069
    Abstract: Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 13, 2022
    Assignee: ATGEN CO. LTD.
    Inventors: Jae Myun Lee, Joo Chun Yoon, Sang Woo Park, Jong Sun Kim
  • Patent number: 11413245
    Abstract: The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: August 16, 2022
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventor: Steven R. Little
  • Patent number: 11413331
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 16, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Patent number: 11414443
    Abstract: The present invention relates to 1-acyl-lysophosphatidyl derivatives of general formula I; in which R is C4 to C30 aliphatic hydrocarbyl chain, R1 is selected from H or C1 to C10 alkyl, preferably C1 to C6 alkyl, R2 is selected from H, C10 to C30 acyl or C1 to C10 alkyl, preferably C1 to C6 alkyl, and R3, when present, is selected from H or C1 to C10 alkyl, preferably C1 to C6 alkyl. These derivatives are intended for the treatment of cancer, in particular melanoma, hepatocarcinoma or GIT carcinomas.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: August 16, 2022
    Assignees: USTAV MOLEKULARNI GENETIKY AV CR, V.V.I., SMART BRAIN S.R.O.
    Inventors: Michal Dvorak, Marta Dvorakova, Vit Karafiat, Jan Stursa, Lukas Werner, Lucie Janeckova
  • Patent number: 11406689
    Abstract: The present disclosure provides compositions and methods for improving reproductive health of mammals and increasing milk production from female mammals. The methods involve administering an effective amount of IL-8 to a female mammal such that the reproductive health of the mammal is improved, or milk production from the mammal is increased, or the fat content of the milk is increased. In another aspect the disclosure includes prophylaxis and/or therapy of uterine conditions by administering IL-8 to a female mammal.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 9, 2022
    Assignee: Cornell University
    Inventor: Rodrigo Carvalho Bicalho
  • Patent number: 11401317
    Abstract: The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 2, 2022
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Qiuchuan Zhuang, Xiaohu Fan, Lei Yang, Pingyan Wang
  • Patent number: 11369690
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 28, 2022
    Assignee: ACADEMIA SINICA & KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • Patent number: 11365391
    Abstract: A nucleic acid construct and an immune cell, which harbor nucleic acids encoding a CAR and nucleic acids encoding at least one anti-inflammatory or immunosuppressant protein and methods of using the same in treatment or amelioration of inflammation or immune-mediated autoimmunity are described.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 21, 2022
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Charles L. Sentman, Benjamine H. Arellano
  • Patent number: 11357796
    Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 14, 2022
    Assignee: KITE PHARMA, INC.
    Inventors: John M. Rossi, Adrian I. Bot
  • Patent number: 11344603
    Abstract: The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 31, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Odunayo Omolola Boluwarin Mugisho, Bradford James Duft
  • Patent number: 11337922
    Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: May 24, 2022
    Assignees: BioN Tech SE, Tron—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg Universität Mainz GmbH
    Inventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer
  • Patent number: 11338014
    Abstract: The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: May 24, 2022
    Inventor: Sumayah Jamal
  • Patent number: 11331415
    Abstract: The present invention relates to the unexpected discovery of novel hydrogel formulations that allow for the encapsulation and delivery of living cells and/or drugs to a subject in need thereof. In certain embodiments, the hydrogel compositions of the invention comprise bound bioactive molecules that promote long-term cell viability and allows for the development of vasculature. The invention further provides methods of delivering viable cells and/or drugs to a subject comprising administering the compositions of the invention to the subject in need thereof.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: May 17, 2022
    Assignee: UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
    Inventors: Rachael A. Oldinski, Jennifer N. Etter
  • Patent number: 11324746
    Abstract: The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 10, 2022
    Assignee: AROVELLA THERAPEUTICS LIMITED
    Inventors: Stephen Damment, Richard Franklin, Jorge D. Erusalimsky
  • Patent number: 11324822
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 10, 2022
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Robert Goodenow, Peter Ordentlich
  • Patent number: 11318185
    Abstract: The present invention addresses the problem of finding a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer containing as an active ingredient: (a) a polypeptide consisting of any one of the amino acid sequences represented by SEQ ID NOs: 3 to 45; or (b) a polypeptide comprising one to several amino acid deletions, substitutions or additions in the amino acid sequence of the polypeptide (a); is useful as an agent for treating or preventing cancer, etc.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 3, 2022
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano
  • Patent number: 11311618
    Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 26, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, GLAXOSMITHKLINE BIOLOGICALS SA, SORBONNE UNIVERSITE
    Inventors: Sandra Morel, Charlotte Véronique Pouchy, Benoit Laurent Salomon, Nathalie Raoul Liliane Vanerheyde
  • Patent number: 11311613
    Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 26, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Patent number: 11304990
    Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 19, 2022
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Patent number: 11298380
    Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.
    Type: Grant
    Filed: January 1, 2019
    Date of Patent: April 12, 2022
    Assignees: Khloris Biosciences, Inc., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Nigel G. Kooreman, Joseph C. Wu, Lynne A. Bui
  • Patent number: 11291747
    Abstract: Disclosed are a biosealant system and method for treatment of a pulmonary air leak comprising applying the biosealant system to the locus of the air leak.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: April 5, 2022
    Assignee: The Trustees of Columbia University in The City of New York
    Inventors: Matthew Bacchetta, Brandon Guenthart, Jinho Kim, John O'Neill, Gordana Vunjak-Novakovic
  • Patent number: 11293009
    Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 5, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
  • Patent number: 11285192
    Abstract: The present specification provides compositions of ?-endorphin and adrenocorticotropic hormone (ACTH). These compositions are useful in methods of treating disease.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: March 29, 2022
    Assignee: Adamis Pharmaceuticals Corporation
    Inventors: Charles Peter Lollo, Dennis J. Carlo
  • Patent number: 11278608
    Abstract: Provided herein are nicotine polymer-stabilized nanoparticles, formulations thereof, and vaccines. Also provided herein are methods of treating and/or preventing nicotine addiction in a subject in need thereof.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: March 22, 2022
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Chenming Zhang, Zongmin Zhao, Yun Hu
  • Patent number: 11273204
    Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15R? or derivatives thereof; and uses thereof.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 15, 2022
    Assignees: CYTUNE PHARMA, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventors: Alain Gey, Eric Tartour, David Bechard
  • Patent number: 11260118
    Abstract: The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 1, 2022
    Assignee: Cancer Research Malaysia
    Inventors: San Jiun Chai, Sammuel Chee Yong Fong, Chai Phei Gan, Sathibalan Ponniah, Vyomesh Patel, Sok Ching Cheong, Kue Peng Lim
  • Patent number: 11260116
    Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 1, 2022
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marianne Stanford, Genevieve Weir, Frederic Ors, Leeladhar Sammatur
  • Patent number: 11246908
    Abstract: The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: February 15, 2022
    Assignee: The Johns Hopkins University
    Inventors: T. C. Wu, Chien-Fu Hung, Brandon Krishna Lam
  • Patent number: 11246891
    Abstract: The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 15, 2022
    Assignee: Micro Vascular Tissues, Inc.
    Inventors: Dale R. Peterson, Ralph-Heiko Mattern, Kevin L. Ohashi, Lael J. Pickett, Glen Gong, Mohammad A. El-Kalay
  • Patent number: 11248050
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 15, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
  • Patent number: 11229668
    Abstract: Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: January 25, 2022
    Assignees: NantCell, Inc., Nant Holdings IP, LLC
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Patrick Soon-Shiong, Hing Wong, Wenxin Xu
  • Patent number: 11224573
    Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 18, 2022
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
  • Patent number: 11203630
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Patent number: 11191821
    Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: December 7, 2021
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Robert Seder, Geoffrey Lynn
  • Patent number: 11191746
    Abstract: The present invention relates to a composition for inhibiting the growth of cancer stem cells, which includes ciclesonide or a pharmaceutically acceptable salt thereof as an active ingredient, a pharmaceutical composition or food composition for inhibiting cancer metastasis, or treating or preventing cancer, which includes the composition, and the like. Ciclesonide of the present invention inhibits the growth of breast cancer cells and lung cancer cells, and inhibits the formation of breast cancer stem cells and lung cancer stem cells.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: December 7, 2021
    Assignee: JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Dong-sun Lee, Hack Sun Choi
  • Patent number: 11179420
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 23, 2021
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Eiko Uno, Masayo Yumoto, Mihoko Yoshino, Xuan Trung Ngo, Hiroyuki Nishida, Akiko Uetani
  • Patent number: 11167034
    Abstract: This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 9, 2021
    Assignee: The University of British Columbia
    Inventors: John K. Jackson, Martin E. Gleave, Veronika Schmitt, Claudia Kesch
  • Patent number: 11160848
    Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 2, 2021
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventor: James K. Williams
  • Patent number: 11162072
    Abstract: The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 2, 2021
    Assignees: BIONTECH US INC., Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhuis
    Inventors: Marit M. Van Buuren, Divya Reddy Lenkala, Joost Huibert Van Den Berg, Jessica Kohler, Matthew Goldstein, Ed Fritsch, Renate De Boer, Ton Schumacher, Noor Bakker
  • Patent number: 11161897
    Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: November 2, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Chichi Huang, John Lee, Jill Mooney, Michael Naso
  • Patent number: 11154571
    Abstract: Provided are exosomes sourced from a granulocyte myeloid-derived suppressor cell and an application thereof. The exosomes are named as G-MDSC exo. Also provided is a use of the exosomes in preparing a drug used for suppressing autoimmune diseases. The G-MDSC exo can effectively suppress proliferation of CD4+T cells in vitro, promote induced proliferation of T regulatory (Treg) cells, alleviate foot swelling of model mice having delayed-type hypersensitivity, and suppress attacks of inflammatory bowel disease (IBD) and collagen-induced arthritis (CIA) of the mice.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: October 26, 2021
    Assignee: JIANGSU UNIVERSITY
    Inventors: Shengjun Wang, Yungang Wang, Jie Tian, Ke Rui, Jie Ma, Bin Ma, Xinyi Tang, Huaxi Xu
  • Patent number: 11149071
    Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 19, 2021
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventors: Huashun Li, Baoyong Ren, Peng Liu
  • Patent number: 11149074
    Abstract: The present invention provides a means capable of efficiently manufacturing a fused substance of an Fc protein and a substance of interest (for example, a peptide). Specifically, the present invention provides an azide group-containing Fc protein represented by formula (1): N3-La-Phe-Lb-Fc??(1) wherein N3 represents an azide group; La represents a bond or a divalent group; Phe represents a residue of phenylalanine or a derivative thereof; Lb represents a lysine residue or an arginine residue, or a peptide linker containing two or more amino acid residues having a lysine residue or an arginine residue at/on the N-terminus; and Fc represents an Fc protein; and the like.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 19, 2021
    Assignee: Ajinomoto Co., Inc.
    Inventors: Shigeo Hirasawa, Masumi Taki
  • Patent number: 11130792
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 28, 2021
    Assignee: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Patent number: 11130791
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • Patent number: 11129846
    Abstract: Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: September 28, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Anuradha Ray, Prabir Ray, Timothy B. Oriss, Sally Ellen Wenzel
  • Patent number: 11130809
    Abstract: Provided herein are pharmaceutical formulations for anti-PD-1 antibodies.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: September 28, 2021
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Wei Cao, Junfeng Li, Xiaolin Liu
  • Patent number: 11116771
    Abstract: Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: September 14, 2021
    Assignee: Oncoceutics, Inc.
    Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
  • Patent number: 11116752
    Abstract: Disclosed is a pharmaceutical composition containing a bicyclo-substituted pyrazolone azo derivative or a salt thereof and a preparation method thereof. In particular, the pharmaceutical composition disclosed in the present invention contains (Z)-5-(2-hydroxyl-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalene-2-yl)-1H-pyrazol-4(5H)-ylidene)hydrazino)phenyl)furan-2-carboxylic acid or a pharmaceutically acceptable salt thereof, and at least one filler optionally selected from cellulose, microcrystalline cellulose, lactose and starch. The composition has a good stability, dissolution rate and bioavailability, and the preparation process is simple, economical and quick.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: September 14, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Xinhua Zhang, Daimei Zhang